Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193,394,759
-
Total 13F shares
-
36,886,584
-
Share change
-
+602,821
-
Total reported value
-
$132,788,072
-
Price per share
-
$3.60
-
Number of holders
-
43
-
Value change
-
+$3,191,052
-
Number of buys
-
20
-
Number of sells
-
18
Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2017
As of 30 Jun 2017,
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,886,584 shares.
The largest 10 holders included
QVT Financial LP, LADENBURG THALMANN FINANCIAL SERVICES INC., RTW INVESTMENTS, LP, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co., Inc., BANK OF MONTREAL /CAN/, AXA, K2 PRINCIPAL FUND, L.P., MORGAN STANLEY, and Hudson Bay Capital Management LP.
This page lists
44
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.